Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Disease Progression
  • Disease-Free Survival
  • Humans
  • Middle Aged
  • Rituximab / administration & dosage
  • Treatment Outcome
  • Waldenstrom Macroglobulinemia / drug therapy

Substances

  • Rituximab
  • Dexamethasone
  • Cyclophosphamide